Is Sirolimus Rx FDA approved? The honest answer

Last updated 2026-07-27

Is sirolimus FDA approved, and for what exactly?

Yes, but only for specific medical uses that have nothing to do with aging. Sirolimus was first approved by the FDA in 1999 under the brand name Rapamune, to prevent organ rejection in kidney transplant patients ^[1]. The original approval covers prophylaxis of organ rejection, usually alongside other immunosuppressants like corticosteroids and calcineurin inhibitors. Since then, two more formulations have picked up narrow approvals. Fyarro (sirolimus protein-bound particles) was approved in 2021 for advanced malignant perivascular epithelioid cell tumor, or PEComa, a rare soft-tissue cancer ^[2]. Hyftor (topical sirolimus gel) was approved in 2022 for facial angiofibromas caused by tuberous sclerosis complex, a genetic disorder ^[3]. That's the entire list. Three approved uses, all in the FDA label: transplant rejection, PEComa, and tuberous sclerosis skin lesions. Nowhere in any FDA-approved label does the word 'aging,' 'longevity,' or 'lifespan' appear. If a website or provider tells you sirolimus is 'FDA approved for anti-aging,' that claim is false. It's not a gray area. It's just not in the label.

Is rapamycin the same drug as sirolimus?

Yes. Rapamycin is the generic scientific name for the compound. Sirolimus is that molecule's US Adopted Name, the name used on prescription labels. They are chemically identical. The confusion comes from history. The drug was originally isolated from soil bacteria on Easter Island (Rapa Nui) in the 1970s and named rapamycin after the island. When it moved into clinical use, the pharmaceutical name sirolimus stuck for FDA labeling purposes ^[1]. So when longevity researchers and biohackers say 'rapamycin,' and when a pharmacy label says 'sirolimus,' they're talking about the same compound. Brand names layer on top: Rapamune for the original tablet and oral solution, Fyarro for the cancer formulation, Hyftor for the topical gel. All three contain sirolimus.

Why do people take rapamycin off-label for longevity?

Because the animal data is some of the strongest in the entire aging field, even though the human data doesn't exist yet. The National Institute on Aging's Interventions Testing Program (ITP), which tests candidate longevity compounds across three lab sites in genetically diverse mice, found that rapamycin extended median lifespan in mice even when started late in life. One widely cited ITP result, published in Nature in 2009, showed rapamycin fed starting at 600 days of age (roughly equivalent to a 60-year-old human) extended median lifespan by about 14% in females and 9% in males in that initial cohort, with later ITP cohorts and doses showing extensions as high as the mid-20s percent range in some groups ^[4][5]. Rapamycin works by inhibiting mTOR (mechanistic target of rapamycin), a cellular pathway that regulates growth, metabolism, and autophagy, the process cells use to clear out damaged components. Dialing down mTOR signaling mimics some effects of caloric restriction, one of the most reproducible lifespan-extension interventions in lab animals across species. That's a genuinely exciting mechanism with real mouse data behind it. But mice are not people, and the ITP itself has never run a trial in humans. No completed randomized controlled trial has tested whether low-dose, intermittent rapamycin extends human lifespan or healthspan. That gap is the whole story. Everything past this point is legal, off-label extrapolation, not an approved indication.

Has any human trial tested rapamycin for aging or lifespan?

No completed trial has measured human lifespan extension from rapamycin, and given that such a trial would take decades and enormous funding, it's unlikely to happen soon. What does exist is a small, mechanistic body of human research, mostly short-duration and focused on biomarkers rather than survival. The most cited example is a 2014 study published in Science Translational Medicine, led by Novartis researchers, testing an mTOR inhibitor (a rapamycin analog, RAD001) in elderly volunteers. It found improved influenza vaccine response, a proxy for immune function, in the treated group . That's interesting and consistent with the idea that low-dose mTOR inhibition can boost certain aspects of aging immunity. It is not a lifespan study, and it did not use sirolimus itself. Separately, an observational human cohort effort known as the PEARL trial has collected survey-based and biomarker data from people taking rapamycin intermittently outside a formal randomized design. This kind of self-reported cohort work can flag side effect patterns worth studying further, but it does not establish that rapamycin extends human life, and it isn't blinded or placebo-controlled . Researchers involved in the aging field, including those who ran the ITP work, have been explicit that translating mouse dosing and outcomes to humans is unproven territory ^[4]. So the honest state of the science: strong, repeated, cross-lab mouse lifespan data. Thin, short-term human biomarker data. Zero completed human lifespan trials. Anyone marketing sirolimus as a proven anti-aging therapy in humans is ahead of the evidence.

Is it legal for a doctor to prescribe sirolimus off-label for aging?

Yes. Off-label prescribing is legal in the United States and is common across medicine; the FDA itself acknowledges that 'once a product has been approved for marketing, a physician may prescribe it for uses...that are not included in approved labeling' . The FDA regulates what a manufacturer can claim, not what a licensed physician can prescribe based on their own clinical judgment. That means a physician-reviewed prescription for low-dose sirolimus, dosed intermittently (commonly once weekly, in ranges discussed in the longevity community and by prescribing clinics) sits in the same legal category as prescribing metformin off-label for weight management, or a beta blocker for anxiety instead of heart disease. Legal, but the burden of judgment shifts to the physician and patient, since there is no FDA-reviewed efficacy or long-term safety data at these doses for this purpose. If you're pursuing this route, work with a provider who prescribes and monitors it deliberately, not a source that skips bloodwork and follow-up. A provider-reviewed model, where a licensed clinician evaluates your labs and history before and during use, with fulfillment through a licensed pharmacy, is the responsible version of off-label use. Sirolimus Rx connects patients to that kind of provider review and to a licensed pharmacy partner for fulfillment. It does not compound or manufacture the drug itself.

What are the real risks of off-label rapamycin dosing?

The three risks that come up most, and that any credible provider should discuss before prescribing, are immunosuppression, mouth ulcers, and metabolic changes. Immunosuppression is the drug's core, FDA-labeled mechanism. It is literally approved because it suppresses the immune response that causes organ rejection. At transplant doses, that means real infection risk, and the FDA label for Rapamune carries warnings about increased susceptibility to infection and certain malignancies with chronic immunosuppression ^[1]. At the low, intermittent doses used off-label for longevity, this risk is presumed to be much smaller, since the drug clears the body between weekly doses, but there is no large human safety dataset at these specific doses to confirm how small. Mouth ulcers (stomatitis) are one of the most commonly reported side effects even at standard transplant doses, and they show up in lower-dose longevity protocols too, based on patient-reported observational data . They're usually manageable but can be uncomfortable enough that people adjust dose or timing. Metabolic effects are the third concern. Sirolimus can raise triglycerides and cholesterol and has been associated with new-onset insulin resistance in some transplant patients, part of why the FDA label recommends monitoring lipid levels ^[1]. This is a real tension for the longevity crowd: mTOR inhibition is supposed to improve long-term metabolic health in mouse models, but short-term human data shows lipid and glucose shifts that need monitoring, not that can be ignored. None of this means the drug is unsafe at low, monitored doses. It means unmonitored use is the wrong way to take it. Anyone starting an off-label protocol should get baseline labs (lipid panel, fasting glucose or A1c, kidney function, complete blood count) and repeat them periodically.

How is off-label longevity dosing different from the FDA-approved transplant dose?

Very different, and that difference matters for how you think about risk. The FDA-approved transplant regimen is daily dosing, typically starting with a loading dose and maintaining blood levels in a specific therapeutic range (commonly monitored via trough levels around 4 to 12 ng/mL, adjusted by indication and combination therapy) ^[1]. It's continuous immunosuppression by design, because the goal is to prevent organ rejection every single day. The off-label longevity protocols that circulate in the research and biohacking community use intermittent, once-weekly or every-other-week dosing at doses that are often a fraction of the daily transplant dose. The idea, borrowed partly from the ITP mouse studies and partly from human pharmacokinetic reasoning, is that a weekly pulse might hit the mTOR pathway hard enough to get autophagy and metabolic benefits without maintaining the kind of continuous immunosuppression that raises infection risk. That's a plausible pharmacological argument. It is not a proven one in a completed human outcomes trial. If you're mapping out an actual regimen, start with a dosage guide and a dosage calculator built around the intermittent protocols discussed in the literature, and talk your specific numbers through with a prescriber rather than copying a forum post.

What does 'provider-reviewed' mean if the drug isn't FDA approved for this use?

It means a licensed clinician looks at your health history and labs and makes an individualized judgment call. That's the same legal mechanism that underlies all off-label prescribing in the US. FDA approval status doesn't disappear when a provider prescribes off-label; it just means the FDA hasn't reviewed efficacy data for that specific use. The physician is the one taking clinical responsibility. A responsible provider-reviewed process for sirolimus longevity use typically includes a health history and medication review (rapamycin interacts with several drugs, including strong CYP3A4 inhibitors and inducers, per the FDA label ^[1]), baseline labs, a defined dosing plan, and a follow-up schedule to recheck labs and adjust. Sirolimus Rx's role in that chain is connecting patients to provider review and to a licensed pharmacy partner for fulfillment. It doesn't compound the drug or set the medical protocol; the prescribing clinician does.

What's the injection or administration process like if I'm prescribed sirolimus?

Most FDA-approved sirolimus (Rapamune) is oral, a tablet or oral solution, not an injection, and that's still the standard form used in most off-label longevity protocols. If your specific formulation or protocol involves reconstitution or injectable administration, follow the exact steps your pharmacy and prescriber give you rather than general internet instructions, since concentration and stability vary by formulation. For readers working through a provider-directed protocol, our other guides cover the mechanics in detail: how to reconstitute Sirolimus Rx, how to inject, injection sites, and cycle length for how long a typical intermittent protocol runs before reassessment.

What should I ask my doctor before starting off-label rapamycin?

Ask directly what evidence supports the specific dose and schedule they're proposing. 'ITP mouse data' and 'proven in humans' are very different standards, and a good provider will say so plainly. Ask what baseline labs they'll run (lipids, glucose or A1c, kidney function, CBC) and how often they'll repeat them. Ask about drug interactions if you take anything else regularly, since sirolimus is metabolized by CYP3A4 and interacts with grapefruit juice, certain antifungals, some antibiotics, and other common medications ^[1]. Ask what mouth ulcer, infection, or lipid changes should trigger a call to them versus waiting for your next check-in. And ask them to be straight about what's FDA-labeled evidence versus off-label extrapolation. If a provider can't clearly separate those two categories for you, that's a red flag, not a marketing problem.

Frequently asked questions

Is Sirolimus Rx FDA approved for anti-aging?

No. Sirolimus (the drug) is FDA approved only for organ transplant rejection prevention, PEComa (Fyarro), and tuberous sclerosis skin lesions (Hyftor). There is no FDA approval for anti-aging, longevity, or lifespan extension in humans; any use for that purpose is off-label and based on animal data plus limited human biomarker studies, not a completed human lifespan trial.

Is rapamycin the same as sirolimus?

Yes, they're the same molecule. Rapamycin is the original scientific and generic name; sirolimus is the pharmaceutical name used on FDA-approved prescription labels like Rapamune. You'll see both terms used interchangeably in research papers and by prescribers, and there's no chemical difference between them.

Has a human study ever shown rapamycin extends lifespan?

No completed human trial has shown rapamycin extends lifespan. The strongest data is in mice, from the NIA Interventions Testing Program, showing double-digit percent median lifespan extension even with late-life dosing. Human studies are limited to short biomarker trials, like a 2014 Science Translational Medicine study showing improved vaccine response in elderly subjects, not survival data.

Why do longevity doctors prescribe an unapproved use?

Because off-label prescribing is legal in the US; the FDA regulates manufacturer marketing claims, not individual physician judgment. A provider can weigh the strong mouse data, the mechanism (mTOR inhibition mimicking caloric restriction), and a patient's individual risk profile, and decide an off-label trial is reasonable, provided the patient understands the evidence gap.

What are the main risks of taking rapamycin off-label?

The three most discussed are immunosuppression (the drug's core mechanism, with infection risk highest at higher or continuous doses), mouth ulcers (stomatitis, reported even at standard doses), and metabolic changes (elevated triglycerides and cholesterol, possible insulin resistance). Intermittent low-dose protocols are thought to reduce but not eliminate these risks; monitoring labs is the standard mitigation.

What is Fyarro and is it the same drug as rapamycin?

Fyarro is a nanoparticle, protein-bound formulation of sirolimus, FDA approved in 2021 for advanced malignant PEComa, a rare soft-tissue cancer. It's chemically related to generic sirolimus and rapamycin but is a distinct formulation and approved indication, not interchangeable with tablets used off-label for longevity.

What is Hyftor used for?

Hyftor is a topical sirolimus gel, FDA approved in 2022 for facial angiofibromas (benign skin lesions) caused by tuberous sclerosis complex, a genetic disorder. It's applied to the skin, unlike the oral tablets used for transplant patients or in off-label longevity protocols.

How is the longevity dose different from the transplant dose?

Transplant dosing is daily and continuous, targeting specific blood trough levels (commonly 4-12 ng/mL depending on regimen) to maintain constant immunosuppression. Off-label longevity protocols typically use intermittent dosing, often weekly, at fractions of the transplant dose, based on the theory that a pulse hits mTOR without sustained immune suppression. This intermittent approach has not been validated in a completed human outcomes trial.

Can I get sirolimus for longevity without a prescription?

No, legally you need a prescription from a licensed provider; sirolimus is a prescription-only drug in the US, not available over the counter. Buying it without a prescription from unregulated sources also means no quality control, no dosing guidance, and no monitoring, which raises real safety risk given the drug's immunosuppressive effects.

What labs should be checked before and during rapamycin use?

A reasonable baseline panel includes a lipid panel (sirolimus can raise triglycerides and cholesterol), fasting glucose or A1c, kidney function, and a complete blood count, per the concerns flagged in the FDA-approved label for transplant use. Providers typically repeat these periodically during off-label use, though there's no standardized monitoring schedule specific to longevity dosing yet.

Does the NIA endorse rapamycin for human aging?

No. The National Institute on Aging funds the Interventions Testing Program that produced the strong mouse lifespan data, but the NIA has not endorsed rapamycin as a proven human anti-aging treatment. The mouse findings are described as a basis for further research, not a clinical recommendation for people.

What does 'off-label' actually mean legally?

It means a drug is being prescribed for a use, dose, or population not listed on its FDA-approved label. The FDA states physicians may prescribe approved products for unapproved uses based on their own medical judgment; off-label prescribing is legal and common across US medicine, though it shifts the evidence burden to the prescriber and patient.

Sources

1. National Institute on Aging Interventions Testing Program: Rapamycin extended median lifespan in genetically heterogeneous mice even when started later in life, across multiple test sites
2. Harrison DE, et al. 'Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.' Nature. 2009;460(7253):392-395.: Foundational ITP study showing rapamycin extends lifespan in mice even with late-life initiation, with specific percent extensions by sex
3. Mannick JB, et al. 'mTOR inhibition improves immune function in the elderly.' Sci Transl Med. 2014;6(268):268ra179.: mTOR inhibitor (RAD001) improved influenza vaccine response in elderly human subjects, a short-term immune biomarker study, not a lifespan trial
4. Kaeberlein M, et al. 'Rapamycin and the mTOR pathway in the biology of aging: from mechanisms to interventions,' and related PEARL cohort survey reporting on Aging-US: Observational human cohort data on self-reported side effects and biomarkers with intermittent rapamycin use, not a randomized lifespan outcomes trial
5. FDA, 'Understanding Unapproved Use of Approved Drugs Off Label': FDA statement that physicians may legally prescribe an approved drug for a use not in the approved labeling